UNITED BIOMEDICAL INC - 15 Nov 2021 Form 4 Insider Report for Vaxxinity, Inc.

Role: 10%+ Owner
Signature: /s/ Mei Mei Hu, As Director and Officer
Issuer symbol: VAXX on OTC
Transactions as of: 15 Nov 2021
Net transactions value: $0
Form type: 4
Filing time: 15 Nov 2021, 17:59:44 UTC
Previous filing: 10 Nov 2021
Next filing: 27 Apr 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VAXX	Class A common stock	Conversion of derivative security		+247,050	+0.48%		51,585,416	15 Nov 2021	Direct	F1
transaction	VAXX	Class A common stock	Conversion of derivative security		+4,212,495			4,212,495	15 Nov 2021	Held by United Biomedical Inc., Asia	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VAXX	Series A preferred stock	Conversion of derivative security		-384,410	-100%		0	15 Nov 2021	Class A common stock	247,050		Direct	F1
transaction	VAXX	Series A preferred stock	Conversion of derivative security		-6,554,643	-100%		0	15 Nov 2021	Class A common stock	4,212,495		Held by United Biomedical Inc., Asia	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares of preferred stock automatically converted into shares of Class A common stock upon closing of the Issuer's initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of preferred stock.
F2	Held by United Biomedical, Asia Inc. ("UBIA"). The Reporting Person, through a subsidiary, holds a majority equity interest in UBIA and may be deemed to be the beneficial owner of the shares held by UBIA. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by UBIA in which the Reporting Person has no pecuniary interest.

Content

Shares of preferred stock automatically converted into shares of Class A common stock upon closing of the Issuer's initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of preferred stock.

Held by United Biomedical, Asia Inc. ("UBIA"). The Reporting Person, through a subsidiary, holds a majority equity interest in UBIA and may be deemed to be the beneficial owner of the shares held by UBIA. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by UBIA in which the Reporting Person has no pecuniary interest.